In Brief

Senate backs pre-tax OTC purchases; infirst Healthcare lands $38M investment; Star Scientific faces fraud allegation; Vitamin Shoppe franchise opens in Panama.

The Senate’s fiscal 2014 budget resolution includes an amendment in support of restoring consumers’ ability to purchase OTC drugs with tax-advantaged spending accounts. Amendment 624, proposed by Sen. Mike Johanns, R-Neb., was agreed to by voice vote March 23 during a marathon session in which the Senate approved the budget resolution in a 50-49 vote. The measure was previously introduced in legislation by Johanns and Rep. Erik Paulsen, R-Minn., to roll back the Patient Protection and Affordable Care Act requirement that consumers get a prescription before being eligible to purchase OTCs with a flexible spending or health savings account. Though the budget resolution sets priorities for federal spending and does not establish appropriation levels, the acceptance of Johanns’ amendment “sent a strong bipartisan message that there is support for improvements to the ACA that enhance cost efficiency in the health care system and respect consumer decisions,” said John Gay, VP of government affairs for the Consumer Healthcare Products Association. Previous legislative attempts to restore pre-tax OTC purchases have stalled Also see "Supreme Court Routes OTC Health Savings Battle Back To Congress" - Pink Sheet, 2 July, 2012..

Consumer health care product developer infirst Healthcare secures an investment of about $38 million (£25 million) to help fund the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By 

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By 

Seven weeks before its action date and after a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By 

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

More from North America